The Dual Role of Autophagy in Crizotinib-Treated ALK<sup>+</sup> ALCL: From the Lymphoma Cells Drug Resistance to Their Demise
Autophagy has been described as harboring a dual role in cancer development and therapy. Depending on the context, it can exert either pro-survival or pro-death functions. Here, we review what is known about autophagy in crizotinib-treated ALK<sup>+</sup> ALCL. We first present our main...
Main Authors: | Estelle Espinos, Raymond Lai, Sylvie Giuriato |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/10/10/2517 |
Similar Items
-
From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
by: Michael T. Werner, et al.
Published: (2017-10-01) -
The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)
by: Ivonne A. Montes-Mojarro, et al.
Published: (2018-04-01) -
Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
by: Dennis Christoph Harrer, et al.
Published: (2020-10-01) -
Role of ALK Inhibitors in Anaplastic Large Cell Lymphoma—Experience from an Indian Center
by: Muthiah Vaikundaraja Indhuja, et al. -
Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib
by: Carolina Valeria Mahuad, et al.
Published: (2016-06-01)